# Amneal Pharmaceuticals, Inc.

Summary updated: 2026-10-02T16:11:25.572235Z
Canonical: https://finbar.com/research/companies/amneal-pharmaceuticals-inc

## Overview

Amneal Pharmaceuticals, Inc. is a pharmaceutical company that develops, manufactures, and commercializes generic and branded medicines. Its businesses span Affordable Medicines, Specialty, and AvKARE: a broad portfolio of generic medicines and biosimilars; branded therapies focused particularly on central nervous system and endocrine disorders; and pharmaceutical, over-the-counter drug, and medical-supply distribution, including to U.S. government and institutional customers. [1](https://app.finbar.com/go?id=P97405285)[2](https://app.finbar.com/go?id=P6867764)[3](https://app.finbar.com/go?id=P18303741)[4](https://app.finbar.com/go?id=P58683254)

The company operates in the United States, India, and Ireland, with activities across research, manufacturing, commercial operations, and active pharmaceutical ingredients. [5](https://app.finbar.com/go?id=P17482042)[6](https://amneal.com/global-presence/) Amneal describes its purpose as making medicine accessible for all and helping patients live better lives through high-quality, accessible medicines. [7](https://amneal.com/about/) For scale, it reported FY2025 net revenue of $3.019 billion; an official company fact sheet published in June 2025 reported more than 8,000 employees. [8](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000011/amrx-20251231.htm)[9](https://amneal.com/wp-content/uploads/2025/07/Amneal-Fact-Sheet-US.pdf)
[1](https://app.finbar.com/go?id=P97405285)[2](https://app.finbar.com/go?id=P6867764)[3](https://app.finbar.com/go?id=P18303741)[4](https://app.finbar.com/go?id=P58683254)[5](https://app.finbar.com/go?id=P17482042)[6](https://amneal.com/global-presence/)[7](https://amneal.com/about/)[8](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000011/amrx-20251231.htm)[9](https://amneal.com/wp-content/uploads/2025/07/Amneal-Fact-Sheet-US.pdf)

## Products & services

Amneal’s product portfolio spans immediate- and extended-release oral medicines, powders, liquids, sterile injectables, nasal sprays, inhalation products, biosimilars, ophthalmics, films, transdermal patches and topical products. It reports more than 280 U.S. product families in Affordable Medicines and focuses in part on complex formulations and manufacturing. Its development capabilities include drug-device combinations, peptides, long-acting injectables and large-volume parenteral bags; 95% of 43 additional products in its pipeline were non-oral solids. [2](https://app.finbar.com/go?id=P6867764)

Named Specialty products include CREXONT® and RYTARY® (extended-release carbidopa/levodopa capsules) for Parkinson’s disease and related parkinsonism, UNITHROID® (levothyroxine sodium) for hypothyroidism, and Brekiya® (dihydroergotamine mesylate), a ready-to-use autoinjector for acute migraine and cluster headache. [3](https://app.finbar.com/go?id=P18303741)[10](https://app.finbar.com/go?id=P114582225) Its biosimilar products include ALYMSYS® (bevacizumab), Releuko® (filgrastim) and Flynetra™ (pegfilgrastim); the company also reported FDA approval of denosumab biosimilars Boncresa™ and Oziltus™ in December 2025. [11](https://app.finbar.com/go?id=P60731734) Respiratory products include albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol. [12](https://app.finbar.com/go?id=P14235605) Other named injectable products include BORUZU™ (ready-to-use bortezomib injection) and TEPADINA® (thiotepa) in a 200 mg multichamber-bag presentation. [13](https://investors.amneal.com/news/press-releases/press-release-details/2025/Amneal-Launches-BORUZU-First-Ready-to-Use-Bortezomib-Injection-for-Multiple-Myeloma-and-Mantle-Cell-Lymphoma/default.aspx)[14](https://investors.amneal.com/news/press-releases/press-release-details/2025/Amneal-Pharmaceuticals-Launches-First-of-Its-Kind-Multichambered-Bag-for-Oncology-with-TEPADINA-Thiotepa-200-mg-2025-jZ6ZsXv03U/default.aspx)

Distribution and service offerings include sales through wholesalers, pharmacies, hospitals and institutions; dedicated field sales and specialty-distribution channels for sterile injectables and biosimilars; and promotion of Specialty products to healthcare providers. AvKARE supplies government customers, repackages bottle and unit-dose pharmaceuticals and vitamins, and wholesales pharmaceuticals, over-the-counter drugs and medical supplies. [15](https://app.finbar.com/go?id=P121370649)[4](https://app.finbar.com/go?id=P58683254) In FY2025, segment revenues were $1,745.5 million for Affordable Medicines (about 57.8% of consolidated revenue), $528.5 million for Specialty (about 17.5%) and $744.7 million for AvKARE (about 24.7%). These figures are by segment; product-level revenue percentages were not reported. [16](https://app.finbar.com/go?id=T6707396)
[2](https://app.finbar.com/go?id=P6867764)[3](https://app.finbar.com/go?id=P18303741)[10](https://app.finbar.com/go?id=P114582225)[11](https://app.finbar.com/go?id=P60731734)[12](https://app.finbar.com/go?id=P14235605)[15](https://app.finbar.com/go?id=P121370649)[4](https://app.finbar.com/go?id=P58683254)[16](https://app.finbar.com/go?id=T6707396)[13](https://investors.amneal.com/news/press-releases/press-release-details/2025/Amneal-Launches-BORUZU-First-Ready-to-Use-Bortezomib-Injection-for-Multiple-Myeloma-and-Mantle-Cell-Lymphoma/default.aspx)[14](https://investors.amneal.com/news/press-releases/press-release-details/2025/Amneal-Pharmaceuticals-Launches-First-of-Its-Kind-Multichambered-Bag-for-Oncology-with-TEPADINA-Thiotepa-200-mg-2025-jZ6ZsXv03U/default.aspx)

## Geographic presence

Amneal Pharmaceuticals is headquartered in Bridgewater, New Jersey. Its U.S. facilities span New Jersey, New York, Kentucky, Tennessee, and Pennsylvania, and include manufacturing, research and development, distribution, warehouse, and office sites. Outside the U.S., the company has facilities in Ireland and India: its listed locations include Cashel County, Tipperary, and sites in Gujarat, Telangana, Andhra Pradesh, and Maharashtra, serving manufacturing, R&D, office, or warehousing functions. [17](https://app.finbar.com/go?id=T330353)

The company reports nearly 2,500 employees in the U.S. and more than 6,000 outside the U.S., primarily in India and Ireland. Its 2025 Form 10-K describes U.S. markets and channels, including federal, retail, and institutional distribution, but does not provide revenue by country or region. Most products are manufactured at company facilities in New York, New Jersey, and India; the company also identifies a third-party supplier in Taiwan. [8](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000011/amrx-20251231.htm) [18](https://app.finbar.com/go?id=P103415966)
[17](https://app.finbar.com/go?id=T330353)[18](https://app.finbar.com/go?id=P103415966)[8](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000011/amrx-20251231.htm)

## Business segments

Amneal Pharmaceuticals reports three business segments. **Affordable Medicines** comprises retail generics, injectables, and biosimilars; it generated approximately **57.8%** of FY2025 consolidated revenue. **Specialty** focuses primarily on branded medicines for central nervous system and endocrine disorders, with products also grouped in hormonal/allergy and other therapeutic categories; it contributed approximately **17.5%**. **AvKARE** distributes pharmaceuticals and other products to U.S. federal-government, retail, and institutional markets, including government-label and institutional channels; it contributed approximately **24.7%**. [19](https://app.finbar.com/go?id=P120150682)[20](https://app.finbar.com/go?id=T37326)

The company retained these three reportable segments in its Q2 2026 filing. Its dosage-form, therapeutic-class, and distribution-channel categories are further breakdowns within the segments, rather than additional reportable segments. [21](https://app.finbar.com/go?id=P150385486)[22](https://app.finbar.com/go?id=P150385455)
[19](https://app.finbar.com/go?id=P120150682)[20](https://app.finbar.com/go?id=T37326)[21](https://app.finbar.com/go?id=P150385486)[22](https://app.finbar.com/go?id=P150385455)

## Company history

Amneal Pharmaceuticals was founded in 2002 by brothers Chirag and Chintu Patel. In 2007, it expanded through the acquisition of generic-drug distributor Akyma Pharmaceuticals and a New Jersey liquid-generics manufacturing plant, adding production capacity and rights to 18 prescription products. [7](https://amneal.com/about/)[23](https://investors.amneal.com/news/press-releases/press-release-details/2007/Amneal-Announces-Acquisition-of-Akyma-Pharmaceuticals/default.aspx)[24](https://investors.amneal.com/news/press-releases/press-release-details/2007/Amneal-Completes-Acquisition-of-Liquid-Form-Generic-Pharmaceuticals-Manufacturing-Plant/default.aspx)

A major turning point came in 2017–2018, when Amneal agreed to combine with Impax Laboratories; the transaction closed on May 4, 2018, creating the publicly listed Amneal Pharmaceuticals, Inc. [25](https://investors.amneal.com/news/press-releases/press-release-details/2017/Amneal-And-Impax-To-Combine/default.aspx)[26](https://investors.amneal.com/news/press-releases/press-release-details/2018/Amneal-and-Impax-Complete-Business-Combination/default.aspx) The company later broadened its distribution and specialty-pharmaceutical operations, acquiring a majority interest in AvKARE in 2020 and completing the acquisition of a 98% interest in Kashiv Specialty Pharmaceuticals in 2021. [27](https://amneal.com/innovating-access/our-timeline/)[28](https://investors.amneal.com/news/press-releases/press-release-details/2021/Amneal-Completes-Acquisition-of-Kashiv-Specialty-Pharmaceuticals/default.aspx) In 2026, Amneal completed its acquisition of Kashiv BioSciences, expanding further into biosimilars. [29](https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Completes-Acquisition-of-Kashiv-BioSciences-Creating-a-Global-Biosimilar-Leader/default.aspx)
[7](https://amneal.com/about/)[23](https://investors.amneal.com/news/press-releases/press-release-details/2007/Amneal-Announces-Acquisition-of-Akyma-Pharmaceuticals/default.aspx)[24](https://investors.amneal.com/news/press-releases/press-release-details/2007/Amneal-Completes-Acquisition-of-Liquid-Form-Generic-Pharmaceuticals-Manufacturing-Plant/default.aspx)[25](https://investors.amneal.com/news/press-releases/press-release-details/2017/Amneal-And-Impax-To-Combine/default.aspx)[26](https://investors.amneal.com/news/press-releases/press-release-details/2018/Amneal-and-Impax-Complete-Business-Combination/default.aspx)[27](https://amneal.com/innovating-access/our-timeline/)[28](https://investors.amneal.com/news/press-releases/press-release-details/2021/Amneal-Completes-Acquisition-of-Kashiv-Specialty-Pharmaceuticals/default.aspx)[29](https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Completes-Acquisition-of-Kashiv-BioSciences-Creating-a-Global-Biosimilar-Leader/default.aspx)

## Sources

1. [Amneal Pharmaceuticals, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P97405285)
2. [Amneal Pharmaceuticals, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P6867764)
3. [Amneal Pharmaceuticals, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P18303741)
4. [Amneal Pharmaceuticals, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P58683254)
5. [Amneal Pharmaceuticals, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P17482042)
6. [amneal.com](https://amneal.com/global-presence/)
7. [amneal.com](https://amneal.com/about/)
8. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000011/amrx-20251231.htm)
9. [amneal.com](https://amneal.com/wp-content/uploads/2025/07/Amneal-Fact-Sheet-US.pdf)
10. [Amneal Pharmaceuticals, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P114582225)
11. [Amneal Pharmaceuticals, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P60731734)
12. [Amneal Pharmaceuticals, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P14235605)
13. [investors.amneal.com](https://investors.amneal.com/news/press-releases/press-release-details/2025/Amneal-Launches-BORUZU-First-Ready-to-Use-Bortezomib-Injection-for-Multiple-Myeloma-and-Mantle-Cell-Lymphoma/default.aspx)
14. [investors.amneal.com](https://investors.amneal.com/news/press-releases/press-release-details/2025/Amneal-Pharmaceuticals-Launches-First-of-Its-Kind-Multichambered-Bag-for-Oncology-with-TEPADINA-Thiotepa-200-mg-2025-jZ6ZsXv03U/default.aspx)
15. [Amneal Pharmaceuticals, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P121370649)
16. [Amneal Pharmaceuticals, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=T6707396)
17. [Amneal Pharmaceuticals, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=T330353)
18. [Amneal Pharmaceuticals, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P103415966)
19. [Amneal Pharmaceuticals, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P120150682)
20. [Amneal Pharmaceuticals, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=T37326)
21. [Amneal Pharmaceuticals, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P150385486)
22. [Amneal Pharmaceuticals, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P150385455)
23. [investors.amneal.com](https://investors.amneal.com/news/press-releases/press-release-details/2007/Amneal-Announces-Acquisition-of-Akyma-Pharmaceuticals/default.aspx)
24. [investors.amneal.com](https://investors.amneal.com/news/press-releases/press-release-details/2007/Amneal-Completes-Acquisition-of-Liquid-Form-Generic-Pharmaceuticals-Manufacturing-Plant/default.aspx)
25. [investors.amneal.com](https://investors.amneal.com/news/press-releases/press-release-details/2017/Amneal-And-Impax-To-Combine/default.aspx)
26. [investors.amneal.com](https://investors.amneal.com/news/press-releases/press-release-details/2018/Amneal-and-Impax-Complete-Business-Combination/default.aspx)
27. [amneal.com](https://amneal.com/innovating-access/our-timeline/)
28. [investors.amneal.com](https://investors.amneal.com/news/press-releases/press-release-details/2021/Amneal-Completes-Acquisition-of-Kashiv-Specialty-Pharmaceuticals/default.aspx)
29. [investors.amneal.com](https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Completes-Acquisition-of-Kashiv-BioSciences-Creating-a-Global-Biosimilar-Leader/default.aspx)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.